BEYOND AIR INC (XAIR)

Company Profile

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in developing a platform for nitric oxide generators and delivery systems. The company is headquartered in Garden City, New York and currently employs 107 full-time employees. The company went IPO on 2019-05-07. The firm has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.

Company Info

BEYOND AIR INC

900 Stewart Avenue, Suite 301

Garden City NEW YORK 11530

P: 15166658200

CEO: Steven Lisi

Employees: 107

Website: https://www.beyondair.net/